Advertisement

Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE

  • Nibhriti DasEmail author
  • Bintili Biswas
  • Rohan Khera
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)

Abstract

For the last two decades, there had been remarkable advancement in understanding the role of complement regulatory proteins in autoimmune disorders and importance of complement inhibitors as therapeutics. Systemic lupus erythematosus is a prototype of systemic autoimmune disorders. The disease, though rare, is potentially fatal and afflicts women at their reproductive age. It is a complex disease with multiorgan involvement, and each patient presents with a different set of symptoms. The diagnosis is often difficult and is based on the diagnostic criteria set by the American Rheumatology Association. Presence of antinuclear antibodies and more specifically antidouble-stranded DNA indicates SLE. Since the disease is multifactorial and its phenotypes are highly heterogeneous, there is a need to identify multiple noninvasive biomarkers for SLE. Lack of validated biomarkers for SLE disease activity or response to treatment is a barrier to the efficient management of the disease, drug discovery, as well as development of new therapeutics. Recent studies with gene knockout mice have suggested that membrane-bound complement regulatory proteins (CRPs) may critically determine the sensitivity of host tissues to complement injury in autoimmune and inflammatory disorders. Case-controlled and follow-up studies carried out in our laboratory suggest an intimate relation between the level of DAF, MCP, CR1, and CD59 transcripts and the disease activity in SLE. Based on comparative evaluation of our data on these four membrane-bound complement regulatory proteins, we envisaged CR1 and MCP transcripts as putative noninvasive disease activity markers and the respective proteins as therapeutic targets for SLE. Following is a brief appraisal on membrane-bound complement regulatory proteins DAF, MCP, CR1, and CD59 as biomarkers and therapeutic targets for SLE.

Keywords

Membrane Cofactor Protein Complement Regulatory Protein Short Consensus Repeat CD59 Transcript Passive Arthus Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ahearn JM, Fearon DT (1989) Structure and function of the C receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 46:183–219PubMedGoogle Scholar
  2. Astier AL (2008) T-cell regulation by CD46 and its relevance in multiple sclerosis. Immunology 124(2):149–154PubMedPubMedCentralGoogle Scholar
  3. Astier A, Trescol-Biemont MC, Azocar O, Lamouille B, Rabourdin-Combe C (2000) Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J Immunol 164:6091–6095PubMedGoogle Scholar
  4. Arora M, Arora R, Tiwari SC, Das N, Srivastava LM (2000) Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 9:127–131PubMedGoogle Scholar
  5. Asghar SS, Pasch MC (2000) Therapeutic inhibition of the complement system. Y2K update. Front Biosci 5:E63–E81PubMedGoogle Scholar
  6. Ballard L, Seya T, Teckman J, Lublin DM, Atkinson JP (1987) A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp45-70). J Immunol 138(11):3850–3855PubMedGoogle Scholar
  7. Bergelson JM, Mohanty JG, Crowell RL, St. John NF, Lublin DM, Finberg RW (1995) Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 69(3):1903–1906PubMedPubMedCentralGoogle Scholar
  8. Birmingham DJ, Gavit KF, McCarty SM, Yu CY, Rovin BH, Nagaraja HN, Hebert LA (2006) Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol 143:274–280PubMedPubMedCentralGoogle Scholar
  9. Brodbeck WG, Liu D, Sperry J et al (1996) Localization of classical and alternative pathway regulatory activity within the decay accelerating factor. J Immunol 156:2528–2533PubMedGoogle Scholar
  10. Byrne JL, Carter GI, Ellis I, Haynes AP, Russell NH (1997) Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant 20(6):517–520PubMedGoogle Scholar
  11. Cashman SM, Ramo K, Kumar-Singh R (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 6(4):e19078PubMedPubMedCentralGoogle Scholar
  12. Cattaneo R (2004) Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens’ magnet. J Virol 78:4385–4388PubMedPubMedCentralGoogle Scholar
  13. Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE (1996) A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur J Immunol 26(3):578–585PubMedGoogle Scholar
  14. Clarkson NA, Kaufman R, Lublin DM, Ward T, Pipkin PA, Minor PD, Evans DJ, Almond JW (1995) Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol 69(9):5497–5501PubMedPubMedCentralGoogle Scholar
  15. Cockburn IA, Mackinnon MJ, O’Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, Rowe JA (2004) A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA 101(1):272–277PubMedGoogle Scholar
  16. Cole J, Housley GA, Dykman TR, MacDermott RP, Atkinson JP (1985) Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci USA 83:859Google Scholar
  17. Cosio FG, Sedmak DD, Mahan JD, Nahman NS (1989) Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 36:100PubMedGoogle Scholar
  18. Cosio FG, Shen XP, Birmingham DJ, Van Aman M, Hebert LA (1990) Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol 145:4198–4206PubMedGoogle Scholar
  19. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR (1995) The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 5:1888–1894PubMedGoogle Scholar
  20. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H (1989) CD59, an Ly-6 like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170:637PubMedGoogle Scholar
  21. Davies KA, Hird V, Stewart S et al (1990) A study of in vivo immune complex formation and clearance in man. J Immunol 144:4613–4620PubMedGoogle Scholar
  22. Davis LS, Patel SS, Atkinson JP, Lipsky PE (1988) Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol 141:2246–2252PubMedGoogle Scholar
  23. Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD (1992) Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 149:768–774PubMedGoogle Scholar
  24. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Oldham ER, Platt JL, Logan JS (1996) Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 61(8):1241–1249PubMedGoogle Scholar
  25. Dorig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295PubMedPubMedCentralGoogle Scholar
  26. Ducruet AF, Mocco J, Mack WJ, Coon AL, Marsh HC, Pinsky DJ, Hickman ZL, Kim GH, Connolly ES Jr (2007) Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. J Med Primatol 36:375–380PubMedGoogle Scholar
  27. Dykman TR, Hatch JA, Aqua MS, Atkinson JP (1985) Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J Immunol 134:1787–1789PubMedGoogle Scholar
  28. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P (2005) CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 280:36342–36354PubMedGoogle Scholar
  29. Endoh M, Yamashina M, Ohi H, Funahashi K, Ikuno T, Yasugi T, Atkinson JP, Okada H (1993) Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 94(1):182–188PubMedPubMedCentralGoogle Scholar
  30. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A (1985) Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312:1594–1599PubMedGoogle Scholar
  31. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 76:5867–5871PubMedGoogle Scholar
  32. Fearon DT (1980) Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152:20–30PubMedPubMedCentralGoogle Scholar
  33. Fearon DT, Kaneko I, Thomson GG (1981) Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med 153:1615–1628PubMedGoogle Scholar
  34. Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W, Taylor RP (1995) Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum 38:190–200PubMedGoogle Scholar
  35. Fernandez-Centeno E, de Ojeda G, Rojo JM, Portoles P (2000) Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells. J Immunol 164:4533–4542PubMedGoogle Scholar
  36. Fingeroth JD, Heath ME, Ambrosino DM (1989) Proliferation of resting B cells is modulated by CR2 and CR1. Immunol Lett 21:291–301PubMedGoogle Scholar
  37. Fodor WL, Williams BL, Matis LA, Madri JA, Rollins SA, Knight JW, Velander W, Squinto SP (1994) Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 91(23):11153–11157PubMedGoogle Scholar
  38. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Liu YJ, Rabourdin-Combe C (1997) Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 186:813PubMedPubMedCentralGoogle Scholar
  39. Fujita T, Inoue T, Ogawa K, Lida K, Tamura N (1987) The mechanism of DAF. DAF inhibits the assembly of the C3 convertases by dissociating C2a and Bb. J Exp Med 166:1221–1228PubMedGoogle Scholar
  40. Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A (2000) Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 192(12):1797–1808PubMedPubMedCentralGoogle Scholar
  41. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, Stetler-Stevenson MA, Siebenlist U, Kelly K (1996) CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157:5438–5447PubMedGoogle Scholar
  42. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589–601PubMedPubMedCentralGoogle Scholar
  43. Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP (2004) Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 95:185–192PubMedGoogle Scholar
  44. Hamann J, Vogel B, van Schijndel GM, van Lier RA (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184:1185–1189PubMedGoogle Scholar
  45. Hamann L, Stamme C, Ulmer AJ, Schumann RR (2002) Inhibition of LPS-induced activation of alveolar macrophages by high concentrations of LPS-binding protein. Biochem Biophys Res Commun 295(2):553–560PubMedGoogle Scholar
  46. Harris CL, Rushmere NK, Morgan BP (1999) Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J 341(Pt 3):821–829PubMedPubMedCentralGoogle Scholar
  47. Hebert LA (1991) The clearance of immune complexes from the circulation of man and other primates. Am J Kidney Dis 17:352–361PubMedGoogle Scholar
  48. Heine-Suner D, Diaz-Guillen MA, de Villena FP, Robledo M, Benitez J, Rodriguez de Cordoba S (1997) A high-resolution map of the regulator of the complement activation gene cluster on 1q32 that integrates new genes and markers. Immunogenetics 45:422–427PubMedGoogle Scholar
  49. Hideshima T, Okada N, Okada H (1990) Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 69(3):396–401PubMedPubMedCentralGoogle Scholar
  50. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG (1997) A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol 158:2872–2881PubMedGoogle Scholar
  51. Hindmarsh EJ, Marks RM (1998) Decay accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 28:1052PubMedGoogle Scholar
  52. Hirano A, Kurita-Taniguchi M, Katayama Y, Matsumoto M, Wong TC, Seya T (2002) Ligation of human CD46 with purified complement C3b or F(ab)2 of monoclonal antibodies enhances isoform-specific interferon gamma-dependent nitric oxide production in macrophages. J Biochem 132:83–91PubMedGoogle Scholar
  53. Hoffmann EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stroma. Immunochemistry 6:391Google Scholar
  54. Hoffmann EM, Etlinger HM (1973) Extraction of complement inhibitory factors from erythrocytes of non-human species. J Immunol 111:946PubMedGoogle Scholar
  55. Holers VM, Cole JL, Lublin DM, Seya T, Atkinson JP (1985) Human C3b- and C4b-regulatory proteins: a new multi-gene family. Immunol Today 6:188PubMedGoogle Scholar
  56. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ (1989) Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84(1):7–17PubMedPubMedCentralGoogle Scholar
  57. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381–416PubMedGoogle Scholar
  58. Huang Y, Smith CA, Song H, Morgan BP, Abagyan R, Tomlinson S (2005) Insights into the human CD59 complement binding interface toward engineering new therapeutics. J Biol Chem 280(40):34073–34079PubMedGoogle Scholar
  59. Iida K, Nussenzweig V (1981) Complement receptor is an inhibitor of the complement cascade. J Exp Med 153:1138–1150PubMedGoogle Scholar
  60. Iwata K, Seya T, Ariga H, Nagasawa S (1994) Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary: comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J Immunol 152:3436–3444PubMedGoogle Scholar
  61. Jimenez-Perianez A, Ojeda G, Criado G, Sanchez A, Pini E, Madrenas J, Rojo JM, Portoles P (2005) Complement regulatory protein Crry/p65-mediated signaling in T lymphocytes: role of its cytoplasmic domain and partitioning into lipid rafts. J Leukoc Biol 78:1386–1396PubMedGoogle Scholar
  62. Johnson NM, McNicol MW, Burton-Kee EJ, Mowbray JF (1981) Circulating immune complexes in tuberculosis. Thorax 36(8):610–617PubMedPubMedCentralGoogle Scholar
  63. Johnstone RW, Loveland BE, McKenzie IF (1993) Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 79(3):341–347PubMedPubMedCentralGoogle Scholar
  64. Jones DR, Thompson RJ, Rao SA, Imrie H (1994) An enzyme-linked immunosorbent assay for complement regulatory proteins and membrane-bound immunoglobulins on intact red blood cells. J Immunol Methods 177(1–2):235–242PubMedGoogle Scholar
  65. Jozsi M, Prechl J, Bajtay Z, Erdei A (2002) Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J Immunol 168:2782–2788PubMedGoogle Scholar
  66. Kalli KR, Hsu P, Fearon DT (1994) Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 15:417–431PubMedGoogle Scholar
  67. Kallstrom H, Liszewski MK, Atkinson JP, Jonsson AB (1997) Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol 25:639PubMedGoogle Scholar
  68. Kallstrom H, Islam MS, Berggren PO, Jonsson AB (1998) Cell signaling by the type IV pili of pathogenic Neisseria. J Biol Chem 273:21777PubMedGoogle Scholar
  69. Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K (1996) The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol 70(8):5143–5152PubMedPubMedCentralGoogle Scholar
  70. Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE (1996) Mechanism of suppression of cell-mediated immunity by measles virus. Science 273:228PubMedGoogle Scholar
  71. Katyal M, Sivasankar B, Ayub S, Das N (2003) Genetic and structural polymorphism of complement receptor 1 in normal Indian subjects. Immunol Lett 89:93–98PubMedGoogle Scholar
  72. Kawano M, Seya T, Koni I, Mabuchi H (1999) Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 116:542–546PubMedPubMedCentralGoogle Scholar
  73. Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7:9–18PubMedGoogle Scholar
  74. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP (2003) Activation of human CD41cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421:388–392PubMedGoogle Scholar
  75. Kennedy SP, Rollins SA, Burton WV, Sims PJ, Bothwell AL, Squinto SP, Zavoico GB (1994) Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 57:1494–1501PubMedGoogle Scholar
  76. Khera R, Das N (2009) Complement receptor 1: disease associations and therapeutic implications. Mol Immunol 46(5):761–772PubMedGoogle Scholar
  77. Kinoshita T, Medof ME, Silber R, Nussenzweig V (1985) Distribution of decay accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 162:75PubMedGoogle Scholar
  78. Kinoshita T, Medof ME, Nussenzweig V (1986) Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. J Immunol 136(9):3390–3395PubMedGoogle Scholar
  79. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT (1987) Human C3b/C4b receptor (CR1): demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 165:1095–1112PubMedGoogle Scholar
  80. Kojima A, Iwata K, Seya T, Matsumoto M, Ariga H, Atkinson JP, Nagasawa S (1993) Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 151:1519PubMedGoogle Scholar
  81. Kroshus TJ, Bolman RM III, Dalmasso AP, Rollins SA, Guilmette ER, Williams BL, Squinto SP, Fodor WL (1996) Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 61:1513–1521PubMedGoogle Scholar
  82. Kurita-Taniguchi M, Fukui A, Hazeki K et al (2000) Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. J Immunol 165:5143–5152PubMedGoogle Scholar
  83. Lee SW, Bonnah RA, Higashi DL, Atkinson JP, Milgram SL, So M (2002) CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae. J Cell Biol 156:951–957PubMedPubMedCentralGoogle Scholar
  84. Li L, Spendlove I, Morgan J, Durrant LG (2001) CD55 is over-expressed in the tumour environment. Br J Cancer 84:80–86PubMedPubMedCentralGoogle Scholar
  85. Liszewski MK, Post TW, Atkinson JP (1991) Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9:431–455PubMedGoogle Scholar
  86. Liu CC, Ahearn JM (2009) The search for lupus biomarkers. Best Pract Res Clin Rheumatol 23(4):507–523PubMedPubMedCentralGoogle Scholar
  87. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD et al (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201(4):567–577PubMedPubMedCentralGoogle Scholar
  88. Longhi MP, Harris CL, Morgan BP, Gallimore A (2006) Holding T cells in check–a new role for complement regulators? Trends Immunol 27(2):102–108PubMedGoogle Scholar
  89. Lublin DM, Liszewski MK, Post TW, Arce MA, Le Beau MM, Rebentisch MB, Lemons RS, Seya T, Atkinson JP (1988) Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP): evidence for inclusion in the multi-gene family of complement regulatory proteins. J Exp Med 168:181PubMedGoogle Scholar
  90. Ludford-Menting MJ, Thomas SJ, Crimeen B, Harris LJ, Loveland BE, Bills M, Ellis S, Russell SM (2002) A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J Biol Chem 277:4477–4484PubMedGoogle Scholar
  91. Ludford-Menting MJ, Oliaro J, Sacirbegovic F et al (2005) A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity 22:737–748PubMedGoogle Scholar
  92. Manchester M, Gairin JE, Patterson JB, Alvarez J, Liszewski MK, Eto DS, Atkinson JP, Oldstone MB (1997) Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1-2. Virology 233(1):174–184PubMedGoogle Scholar
  93. Manchester M, Eto D, Valsamakis A, Liton P, Fernandez-Munoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB (2000) Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol 74:3967PubMedPubMedCentralGoogle Scholar
  94. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM et al (1996a) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178–1188PubMedGoogle Scholar
  95. Manzi L, Montaño R, Abad MJ, Arsenak M, Romano E, Taylor P (2006) Expression of human soluble complement receptor 1 by a pig endothelial cell line inhibits lysis by human serum. Xenotransplantation 13(1):75–79PubMedGoogle Scholar
  96. Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B (2002) Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 3:659–666PubMedGoogle Scholar
  97. Marquart HV, Svendsen A, Rasmussen JM, Nielsen CH, Junker P, Svehag SE, Leslie RG (1995) Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 101:60–65PubMedPubMedCentralGoogle Scholar
  98. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, Morgan BP (1994) Role of CD59 in experimental glomerulonephritis in rats. Kidney Int 46:191–200PubMedGoogle Scholar
  99. McKusick VA (2001) The anatomy of the human genome: a neo-Vesalian basis for medicine in the 21st century. JAMA 286(18):2289–2295PubMedGoogle Scholar
  100. Medof ME, Iida K, Mold C, Nussenzweig V (1982) Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 156:1739–1754PubMedGoogle Scholar
  101. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ (1990) Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b–8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1PubMedPubMedCentralGoogle Scholar
  102. Meri S, Waldmann H, Lachmann PJ (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65(5):532–537PubMedGoogle Scholar
  103. Metcalfe RA, McIntosh RS, Morgan BP, Levin JL, Weetman AP (1996) The effect of soluble complement receptor 1 (sCR1) and human thyroid antibodies on the course of experimental autoimmune thyroiditis in rats. Autoimmunity 23:1–8PubMedGoogle Scholar
  104. Mikata S, Miyagawa S, Yoshitatsu M, Ikawa M, Okabe M, Matsuda H, Shirakura R (1998) Prevention of hyperacute rejection by phosphatidylinositol-anchored mini-complement receptor type 1. Transplant Immunol 6:107–110Google Scholar
  105. Mitchell JA, Sim RB, Sim E (1989) CR1 polymorphism in hydralazine-induced systemic lupus erythematosus: DNA restriction fragment length polymorphism. Clin Exp Immunol 78:354–358PubMedPubMedCentralGoogle Scholar
  106. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC (2002) Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161:1077–1086PubMedPubMedCentralGoogle Scholar
  107. Miyagawa S, Shirakura R, Matsumiya G, Nakata S, Matsuda H, Hatanaka M, Matsumoto M, Seya T (1994) Possibility of prevention of hyperacute rejection by DAF and CD59 in xenotransplantation. Transplant Proc 26(3):1235–1238PubMedGoogle Scholar
  108. Miyagawa S, Shirakura R, Nakata S, Izutani H, Matsuda H, Iwata K, Nagasawa S, Terado A, Hatanaka M, Matsumoto M et al (1995) Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Transplant Proc 27(1):328–329PubMedGoogle Scholar
  109. Mizuno M, Nishikawa K, Spiller OB, Morgan BP, Okada N, Okada H, Matsuo S (2001) Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum 44(10):2425–2434PubMedGoogle Scholar
  110. Moran P, Beasley H, Gorrell A, Martin E, Gribling P, Fuchs H, Gillett N, Burton LE, Caras IW (1992) Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 149(5):1736–1743PubMedGoogle Scholar
  111. Morgan BP, Meri S (1994) Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15:369–396PubMedGoogle Scholar
  112. Moulds JM, Reveille JD, Arnett FC (1996) Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups. Clin Exp Immunol 105:302–305PubMedPubMedCentralGoogle Scholar
  113. Nangaku M (2003) Complement regulatory proteins: are they important in disease? J Am Soc Nephrol 14(9):2411–2413PubMedGoogle Scholar
  114. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Morgan BP, Johnson RJ, Couser WG (1998) CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 9:590–597PubMedGoogle Scholar
  115. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67:6025PubMedPubMedCentralGoogle Scholar
  116. Nelson RA Jr (1953) The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 118(3077):733–737PubMedGoogle Scholar
  117. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184PubMedGoogle Scholar
  118. Nose M, Katoh M, Okada N, Kyogoku M, Okada H (1990) Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70:145PubMedPubMedCentralGoogle Scholar
  119. Ogelsby TJ, Allen CJ, Liszewski MK, Whiti DJG, Atkinson JP (1992) Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 175:1547Google Scholar
  120. Okada N, Harada R, Fujita T, Okada H (1989) A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1:205PubMedGoogle Scholar
  121. Okada N, Liszewski MK, Atkinson JP, Caparon M (1995) Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci USA 92:2489PubMedGoogle Scholar
  122. Oliaro J, Pasam A, Waterhouse NJ, Browne KA, Ludford-Menting MJ, Trapani JA, Russell SM (2006) Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proc Natl Acad Sci USA 103:18685–18690PubMedGoogle Scholar
  123. Oudin S, Libyh MT, Goossens D, Dervillez X, Philbert F, Reveil B, Bougy F, Tabary T, Rouger P, Klatzmann D, Cohen JH (2000) A soluble recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes. J Immunol 164:1505–1513PubMedGoogle Scholar
  124. Petranka JG, Fleenor DE, Sykes K, Kaufman RE, Rosse WF (1992) Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci USA 89(17):7876–7879, Erratum in: Proc Natl Acad Sci USA 1993 Jun 15; 90(12):5878PubMedGoogle Scholar
  125. Picard MD, Pettey CL, Marsh HC, Thomas LJ (2000) Characterization of N-linked oligosaccharides bearing sialyl lewis xmoieties on an alternatively glycosylated form of soluble complement receptor type 1 (sCR1). Biotechnol Appl Biochem 31(Pt 1):5–13PubMedGoogle Scholar
  126. Price JD, Schaumburg J, Sandin C, Atkinson JP, Lindahl G, Kemper C (2005) Induction of a regulatory phenotype in human CD4+ T cells by streptococcal M protein. J Immunol 175:677–684PubMedGoogle Scholar
  127. Qian YM, Haino M, Kelly K, Song WC (1999) Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98:303–311PubMedPubMedCentralGoogle Scholar
  128. Quigg RJ, Nicholson-Weller A, Cybulsky AV, Badalamenti J, Salant DJ (1989) Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol 142(3):877–882PubMedGoogle Scholar
  129. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AE 3rd, Lo CF (1995) Complement regulation in the rat glomerulus: crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int 48(2):412–421PubMedGoogle Scholar
  130. Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, DiMartino MJ, Vernick J, Fong KL, Feuerstein G (1992) Role of complement in endotoxin/plateletactivating factor-induced lung injury. J Immunol 149:1744–1750PubMedGoogle Scholar
  131. Reid KBM, Bentley DR, Campbell RD, Chung LP, Sim RB, Kristensen T, Tack BF (1986) Complement system proteins which interact with Cab or C4b. A superfamily of structurally related proteins. Immunol Today 7:230PubMedGoogle Scholar
  132. Richaud-Patin Y, Pérez-Romano B, Carrillo-Maravilla E, Rodriguez AB, Simon AJ, Cabiedes J, Jakez-Ocampo J, Llorente L, Ruiz-Argüelles A (2003) Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Lett 88(2):95–99PubMedGoogle Scholar
  133. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25(11):1265–1275PubMedPubMedCentralGoogle Scholar
  134. Rittershaus CW, Thomas LJ, Miller DP, Picard MD, Geoghegan-Barek KM, Scesney SM, Henry LD, Sen AC, Bertino AM, Hannig G, Adari H, Mealey RA, Gosselin ML, Couto M, Hayman EG, Levin JL, Reinhold VN, Marsh HC Jr (1999) Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J Biol Chem 274(16):11237–11244PubMedGoogle Scholar
  135. Rodriguez de Cordoba S, Lublin DM, Rubenstein P, Atkinson JP (1985) Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med 161:1189PubMedGoogle Scholar
  136. Rollins SA, Zhao J, Ninomiya H, Sims PJ (1991) Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 146(7):2345–2351PubMedGoogle Scholar
  137. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50PubMedGoogle Scholar
  138. Rooney A, Davies A, Griffiths D, Williamst JD, Daviest M, Merit S, Lachmannt PJ, Morgan BP (1991) The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol 83:251–256PubMedPubMedCentralGoogle Scholar
  139. Rooney IA, Davies A, Morgan BP (1992) Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology 75(3):499–506PubMedPubMedCentralGoogle Scholar
  140. Ross GD, Lambris JD, Cain JA, Newman SL (1982) Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol 129:2051–2060PubMedGoogle Scholar
  141. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ (1985) Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 135:2005–2014PubMedGoogle Scholar
  142. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P (1999) CD46 is a cellular receptor for human herpesvirus 6. Cell 99:817PubMedGoogle Scholar
  143. Seya T, Atkinson JP (1989) Functional properties of membrane cofactor protein of complement. Biochem J 264:581PubMedPubMedCentralGoogle Scholar
  144. Seya T, Turner JR, Atkinson JP (1986) Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 163:837PubMedGoogle Scholar
  145. Seya T, Ballard L, Bora N, MacNearney T, Atkinson JP (1988) Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. Eur J Immunol 18:1289PubMedGoogle Scholar
  146. Seya T, Okada M, Matsumoto M, Hong KS, Kinoshita T, Atkinson JP (1991) Preferential activation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol Immunol 28:1137PubMedGoogle Scholar
  147. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM (1992) Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 149:3535–3541PubMedGoogle Scholar
  148. Shibata T, Cosio FG, Brimingham DJ (1991) Complement activation induces expression of decay accelerating factor on human mesangial cells. J Immunol 147:3901–3908PubMedGoogle Scholar
  149. Shibuya T, Izuchi K, Kuroiwa A, Harada H, Kumamoto A, Shirakawa K (1991) Study on nonspecific immunity in pregnant women: II. Effect of hormones on chemiluminescence response of peripheral blood phagocytes. Am J Reprod Immunol 26(2):76–81PubMedGoogle Scholar
  150. Sivasankar B, Dinda AK, Tiwari SC, Srivastava LM, Das N (2004) Modulation of urinary CR1 in systemic lupus erythematosus. Lupus 13:228–233PubMedGoogle Scholar
  151. Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30(Pt6):1037–1041PubMedGoogle Scholar
  152. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, Miwa T, Madaio MP, Song WC (2001) Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 167:2791–2797PubMedGoogle Scholar
  153. Sparrow RL, McKenzie IF (1983) Human ‘Ia’ antigen populations defined by monoclonal antibodies. J Immunogenet 10(3):179–189PubMedGoogle Scholar
  154. Spendlove I, Li L, Carmichael J, Durrant L (1999) Decay accelerating factor(CD55): a target for cancer vaccines? Cancer Res 59:2282–2286PubMedGoogle Scholar
  155. Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG (2006) Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother 55(8):987–995PubMedGoogle Scholar
  156. Stammberger U, Hamacher J, Hillinger S, Schmid RA (2000) sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation. J Thorac Cardiovasc Surg 120:1078–1084PubMedGoogle Scholar
  157. Sugita Y, Nakano Y, Tomita M (1988) Isolation from human erythrocytes a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 147:633, TokyoGoogle Scholar
  158. Sugita Y, Ito K, Shiozuka K, Suzuki H, Gushima H, Tomita M, Masuho Y (1994) Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunology 82:34–41PubMedPubMedCentralGoogle Scholar
  159. Tamai H, Matsuo S, Fukatsu A, Nishikawa K, Sakamoto N, Yoshioka K, Okada N, Okada H (1991) Localization of 20-kDa homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. Clin Exp Immunol 84:256–262PubMedPubMedCentralGoogle Scholar
  160. Tarkowski A, Trollmo C, Seifert PS, Hansson GK (1992) Expression of decay-accelerating factor on synovial lining cells in inflammatory and degenerative arthritides. Rheumatol Int 12:201–205PubMedGoogle Scholar
  161. Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A (1999) C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 163:5056–5063PubMedGoogle Scholar
  162. Tone M, Walsh LA, Waldmann H (1992) Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 227(3):971–976PubMedGoogle Scholar
  163. Tosello AC, Mary F, Amiot M, Bernard A, Mary D (1998) Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 48:13–27PubMedGoogle Scholar
  164. Turnberg D, Botto M, Lewis M, Zhou W, Sacks SH, Morgan BP, Walport MJ, Cook HT (2004) 59a deficiency exacerbates ischemia-reperfusion injury in mice. Am J Pathol 165(3):825–832PubMedPubMedCentralGoogle Scholar
  165. Vedeler C, Ulvestad E, Bjørge L, Conti G, Williams K, Mørk S, Matre R (1994) The expression of CD59 in normal human nervous tissue. Immunology 82(4):542–547PubMedPubMedCentralGoogle Scholar
  166. Voynova E, Tchorbanov A, Prechl J, Nikolova M, Baleva M, Erdei A, Vassilev T (2008) An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Immunol Lett 116:168–173PubMedGoogle Scholar
  167. Walport M, Ng YC, Lachmann PJ (1987) Erythrocytes transfused into patients with SLE and hemolytic anemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol 69:501–505PubMedPubMedCentralGoogle Scholar
  168. Watanabe M, Morita Y, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Morgan BP, Okada N, Okada H, Matsuo S (2000) CD59 protects rat kidney from complement mediated injury in collaboration with crry. Kidney Int 58(4):1569–1579PubMedGoogle Scholar
  169. Weis JH, Morton CC, Bruns GAP, Weis JJ, Klickstein LB, Wong WW, Fearon DT (1987) A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein Barr virus receptor map to 1q32. J Immunol 138:312–315PubMedGoogle Scholar
  170. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT (1990a) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249(4965):146–151PubMedGoogle Scholar
  171. Weiss L, Fischer E, Haeffner-Cavaillon N, Jouvin MH, Appay MD, Bariety J, Kazatchkine M (1989) The human C3b receptor (CR1). Adv Nephrol Necker Hosp 18:249–269PubMedGoogle Scholar
  172. Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP (2004) Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 50:3035–3044PubMedGoogle Scholar
  173. Wilson JG, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT (1986a) Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 164:50–59PubMedGoogle Scholar
  174. Zaffran Y, Destaing O, Roux A, Ory S, Nheu T, Jurdic P, Rabourdin-Combe C, Astier AL (2001) CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogenactivated protein kinase. J Immunol 167:6780–6785PubMedGoogle Scholar
  175. Zhang H-F, Yu J, Bajwa E, Morrison SL, Tomlinson S (1999) Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 103(1):55–61PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of BiochemistryAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations